-
Something wrong with this record ?
Biomedically relevant chemical constituents of Valeriana officinalis
Jiří Patočka, Jiří Jakl
Language English Country Czech Republic
Document type Review
NLK
Free Medical Journals
from 2003 to 2013
Freely Accessible Science Journals
from 2003 to 2013
ROAD: Directory of Open Access Scholarly Resources
from 2002
- MeSH
- Alkaloids pharmacology classification therapeutic use MeSH
- Analgesics therapeutic use MeSH
- Anticonvulsants therapeutic use MeSH
- Anti-Anxiety Agents therapeutic use MeSH
- Animal Experimentation MeSH
- Hypnotics and Sedatives therapeutic use MeSH
- Iridoids chemistry MeSH
- Valerian chemistry MeSH
- Pentanoic Acids chemistry adverse effects therapeutic use MeSH
- Humans MeSH
- Plant Extracts chemistry MeSH
- Plant Preparations administration & dosage adverse effects therapeutic use MeSH
- Valerianaceae chemistry classification MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Review MeSH
Valerian is used to treat sleeping disorders, restlessness and anxiety, but it seemsonly to work when taken over long periods (several weeks). Some studies have demonstrated that valerian extracts interact with the GABA and benzodiazepine receptors. Valerian is also used traditionally to treat gastrointestinal pain and spastic colitis. There are no long term safety studies. Valerian contains over 150 chemical constituents and many of them are physiologically active, mainly pyridine alkaloids, some organic acids and terpenes, especially the so called valepotriates, esterified iridoid-monoterpenes. As valepotriates may be potential mutagens, valerian should only be used after consultation with a physician. Valerian medication is sometimes recommended as first line treatment when the benefit-risk relation requires it and is often indicated as transition medication during the discontinuation processes involving bromazepam, clonazepam and diazepam, among others.
References provided by Crossref.org
Lit.: 64
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10008314
- 003
- CZ-PrNML
- 005
- 20111210162031.0
- 008
- 101207s2010 xr e eng||
- 009
- AR
- 024 7_
- $a 10.2478/v10136-009-0002-z $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Patočka, Jiří, $d 1939- $7 jn20000401939
- 245 10
- $a Biomedically relevant chemical constituents of Valeriana officinalis / $c Jiří Patočka, Jiří Jakl
- 314 __
- $a Faculty of Health and Social Studies, University of South Bohemia, České Budějovice
- 504 __
- $a Lit.: 64
- 520 9_
- $a Valerian is used to treat sleeping disorders, restlessness and anxiety, but it seemsonly to work when taken over long periods (several weeks). Some studies have demonstrated that valerian extracts interact with the GABA and benzodiazepine receptors. Valerian is also used traditionally to treat gastrointestinal pain and spastic colitis. There are no long term safety studies. Valerian contains over 150 chemical constituents and many of them are physiologically active, mainly pyridine alkaloids, some organic acids and terpenes, especially the so called valepotriates, esterified iridoid-monoterpenes. As valepotriates may be potential mutagens, valerian should only be used after consultation with a physician. Valerian medication is sometimes recommended as first line treatment when the benefit-risk relation requires it and is often indicated as transition medication during the discontinuation processes involving bromazepam, clonazepam and diazepam, among others.
- 650 _2
- $a Valerianaceae $x chemie $x klasifikace $7 D028161
- 650 _2
- $a kozlík (rostlina) $x chemie $7 D014632
- 650 _2
- $a rostlinné extrakty $x chemie $7 D010936
- 650 _2
- $a rostlinné přípravky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D028321
- 650 _2
- $a alkaloidy $x farmakologie $x klasifikace $x terapeutické užití $7 D000470
- 650 _2
- $a kyseliny pentanové $x chemie $x škodlivé účinky $x terapeutické užití $7 D010421
- 650 _2
- $a experimenty na zvířatech $7 D032761
- 650 _2
- $a iridoidy $x chemie $7 D039823
- 650 _2
- $a hypnotika a sedativa $x terapeutické užití $7 D006993
- 650 _2
- $a antikonvulziva $x terapeutické užití $7 D000927
- 650 _2
- $a analgetika $x terapeutické užití $7 D000700
- 650 _2
- $a anxiolytika $x terapeutické užití $7 D014151
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Jakl, Jiří, $d 1981- $7 mzk2009502644
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $g Roč. 8, č. 1 (2010), s. 11-18 $x 1214-021X
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2010/01/02.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 8
- 990 __
- $a 20100409135453 $b ABA008
- 991 __
- $a 20110222092907 $b ABA008
- 999 __
- $a ok $b bmc $g 722209 $s 585298
- BAS __
- $a 3
- BMC __
- $a 2010 $b 8 $c 1 $d 11-18 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $a 2010-19/dkal